Submitted Successfully!
Thank you for your contribution! You can also upload a video entry related to this topic through the link below:
Check Note
Ver. Summary Created by Modification Content Size Created at Operation
1 -- 3239 2022-04-07 11:54:28 |
2 format correct + 55 word(s) 3294 2022-04-08 04:35:45 |
Design Challenges and Limitations of Injectable Hydrogels
Upload a video

Injectable hydrogels (IHs) are smart biomaterials and are the most widely investigated and versatile technologies, which can be either implanted or inserted into living bodies with minimal invasion. Their unique features, tunable structure and stimuli-responsive biodegradation properties make these IHs promising in many biomedical applications, including tissue engineering, regenerative medicines, implants, drug/protein/gene delivery, cancer treatment, aesthetic corrections and spinal fusions. Regarding their current prospective and ongoing research, hydrogel formulations have some limitations in their applications, clinical practices and sustainability. Many hydrogel systems (natural/synthetic), such as thermosensitive hydrogels, are free-flowing sols at a low temperature, while upon raising to body temperature (physiological temperature), they are converted to a stable visco-elastic gel phase, such as poly (phosphazene), pluronic and poly (N-isopropyl acrylamide). 

injectable hydrogels biodegradable polymers chemical and physical crosslinking tissue engineering
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to : , , ,
View Times: 989
Revisions: 2 times (View History)
Update Date: 08 Apr 2022
Table of Contents

    1. Introduction

    Biomaterial with desirable therapeutic efficacy, drug-delivery capabilities and enhanced properties has paved the way for the effective targeted treatment of diseases and injured tissue repair. It has become a promising area of human health-related research in biomedical material, agricultural, environmental, chemical, engineering and other applied sciences [1]. Over the last decade, hydrogels and their desirable biomedical applications, such as biocompatibility, non-toxicity, biodegradability, flexibility, biofunctionality, sol–gel transitions, tunable properties, physico-chemical properties, degree of swelling and porosity, synthesis, crosslinking, drug-encapsulation, sustained/control release of therapeutic agents (drug, proteins, genes, cells, etc.), tissue regeneration/repairing, wound healing, cancer chemotherapy and the treatment of superbug bacterial infections, have been extensively observed and investigated [1][2][3][4]. Hydrogels are a hydrophilic polymer system that has the capability of retaining a significant amount of water and swelling in an aqueous medium. However, due to their three-dimensional (3D) crosslinking structure, they remain insoluble in water and biological fluids [1][4]. The high water content and their polymeric meshwork and side chain maintain their well-defined structures due to their highly adsorptive surfaces, as well as spatiotemporal control over their physico-chemical properties and the release of encapsulated drug from hydrogel cores [5].
    The typical administration of a hydrogel formulation begins from its early use in contact lenses to its extensively developed complicated applications, mostly in tissue engineering and gene/DNA delivery for sustained and controlled drug delivery. Wound healing dressing, sensors, mucoadhesive, bioactive factor delivery, bug targeting and cancer chemotherapy are other typical applications [6]. Extensive research on hydrogel formulations and dosage-form preferences has widened their biomedical applications and availability to consumers. IHs are gaining traction over the traditional intravenous therapies, which have many systemic toxicities in comparison, including myelosuppression, liver or kidney dysfunctions, non-targeted delivery, prolonged/controlled release and neuro- and other organ-toxicities. IHs can competently avoid these problems by releasing drugs at the infective/tumor site or target sites with localized drug toxicities [2][4][7].
    IHs possesses a unique biocompatibility and hydrophilicity, as well as a phase transitions ability—sol (liquid) to gel (solid) to form solid-like gel states to administer and assist in the encapsulation and release of drugs, genes, DNA, proteins and cells in a sustained and controlled manner [8]. They are prepared from natural and synthetic polymers through various mechanisms, such as physical and chemical crosslinking methods (discussed in 1.2 classification and synthesis) into different types with their respective advantages and disadvantages [7]. Some of the characteristics associated with IHs are shown in Figure 1 [9], whereas Figure 2 [10] shows the designated and fabricated IHs for photothermal antitumor therapy.
    Figure 1. (A) Swelling ability of hydrogels from lyophilized state. (B) Example of a gelation time measurement by inverted vial method. (C) Cross-section SEM images of freeze-dried injectable hyaluronic acid hydrogel. (D) Physical interactions and chemical linkages of the chemical structure of an injectable hydrogel. Adapted with permission from ref. [9]. Copyright © 2021 Polymer MDPI.
    Figure 2. Graphical illustration depicting the design and fabrication of injectable hydrogel for photothermal antitumor therapy and following wound repair and regeneration. Adapted with permission from ref. [10]. Copyright © 2020 Theranostics.

    2. Current Trends

    2.1. IHs and Its Application in Drug Delivery System and Biomedical Engineering Applications

    The current trends in biodegradable injectable hydrogel research and its wide application in the biomedical field make it one of the most important therapeutic formulations in drug delivery systems and regenerative medicines—for instance, its application in cartilage regenerations, where its physical properties can be designed such that they can properly match with articular cartilages, in association with their mechanical robustness and scaffold with native tissues. The current research diversifies, proceeds and focuses on the application of gene/drug/DNA/protein delivery, cancer therapy, immunotherapy, tissue regeneration (Figure 3) and engineering, vaccine delivery, implants, stem cell therapy, wound healing and many more—e.g., controlled, prolonged and sustained release formulations [9][11][12][13][14][15][16][17][18][19][20][21][22].
    Figure 3. Schematic illustration of biodegradable injectable hydrogel for tissue regeneration approaches. Cells are isolated from a small biopsy, expanded in vitro and encapsulated in hydrogel precursors, which are subsequently transplanted into the patient by injection using a needle. Hydrogels provide initial structural support and retain cells in the defective area for cell growth, metabolism and new extracellular matrix (ECM) synthesis. The hydrogel is readily degradable when the cells secrete ECM. This strategy enables the clinician to transplant the cell, growth factor and hydrogel combination in a minimally invasive manner. Adapted with permission from ref. [6]. Copyright © 2010 Material by MDPI.

    2.2. Drug Delivery

    Conventional drug delivery approaches are associated with undesirable drug absorption, rapid metabolism, repeated dosing, systemic toxicities and easy degradation under certain physiological conditions. Injectable hydrogel with sustained drug release properties, degradability and tunable physical properties make it a promising smart drug delivery system, which can overcome and optimize all those disadvantages. Biocompatibility, good syringeability with minimal invasiveness and responsiveness to environmental or enzymatic stimuli make these IHs smart therapeutic systems [23]. In comparison with other systemic or topical administrations, drugs using IHs are promising for controlled biodistribution and sustained release purposes. The 3D structure and water dispersed phase hydrogels can encapsulate water-soluble drugs, though water-insoluble drugs can also be loaded. Macromolecular compounds or bioactive molecules, such as genes, peptides, proteins or even living cells or organs can also be entrapped in hydrogels [13][22][24][25]Figure 4 [26] and Figure 5 [27] illustrate drug delivery of IHs.
    Figure 4. Schematic illustration of Uox-loaded PEG-PAEU/HSA hydrogels and their controlled release of Uox for degradation of uric acid crystals in hyperuricemia mice models. Reprinted with permission from ref. [26]. Copyright © 2017 from Journal of Control Release, Elsevier.
    Figure 5. Schematic illustration for the synergistic effect of PLK1shRNA/PEI-Lys and DOX co-loaded hydrogel on a tumor in nude mice. Reprinted with permission from ref. [27]. Copyright © 2014 from Biomaterial, Elsevier.

    2.3. Therapeutic Applications

    2.3.1. Cancer Therapy

    Systemic cytotoxicity is associated with the conventional chemotherapy of cancers. The localized non-invasive chemotherapeutics of IHs can overcome the associated toxicities and ensure drug/protein sustained release at tumor sites. In more detail, these IHs (natural and synthetic polymers) are responsive to certain stimuli, such as pH, temperature and immuno-sensitivity, which can be used for cancer chemotherapy/gene therapy or immune therapy [28][29][30][24][31]. Some of the commercially available synthetic IHs, such as TraceIT® and SpaceOAR®, are therapeutically used for cancerous cell applications, which can protect healthy cells from radiotherapy-induced damage. TraceIT® contains tissue markers and polyethylene glycol (PEG) hydrogel microparticles, with covalently bond iodine, which helps in the visualization and identification of cancerous tissue for up to three months using ultrasound, computed tomography (CT) and magnetic-resonance imaging (MRI). SpaceOAR® hydrogel has also been fabricated to protect normal tissues from radiation during radiotherapy for carcinoma. Hence, improving the persistence and rigidity of natural IHs may have significant importance in the treatment of carcinomas and tumors ((Figure 6) [32] and (Figure 7[28]).
    Figure 6. Depiction of in situ gel formation process and its sustained release of drugs from the hydrogel into tumor cells. Reprinted with permission from ref. [32]. Copyright © 2020 from Drug delivery, Taylor and Francis.
    Figure 7. Schematic diagram showing hydrogel formation. (a) Photograph of excised tumors after mice were euthanized on the 21st day. (b) Changes in relative tumor volume. Reprinted with permission from ref. [28]. Copyright © 2020 Copyright © 2017, International Journal of Biological Macromolecules, Elsevier.

    2.3.2. Wound Healings

    Common clinical traumas are associated with tumors, fractures and diabetes, which often go hand in hand with serious infections, including superbugs. Hydrogel dressings with excellent antibacterial properties, bioadhesiveness, good compatibility and biodegradability are preferred over conventional wound healing. They have been fabricated to control infections, improve angiogenesis and uphold angiogenesis. Hydrogels that are photothermal sensitive have the ability to convert NIR irradiation intensity time, photothermal-initiator concentration ratio, cycling time, etc. Increasing the temperature from >50 °C can inhibit bacterial growth effectively, while at 41–43 °C it accelerates wound closure and healing. Nanoparticles (NPs) of copper (GelMA/BACA–Cu) hydrogels possess good photothermal capability under NIR irradiations. After ten minutes of exposure to NIR, hyperthermia (>55 °C) can efficiently inhibit bacterial growth, while its Cu2+ combination can enhance its antibacterial efficacy. The wound closure rate was 95% in the NIR + GelMA/BACA–Cu NPs hydrogel group, in comparison with the control group, 79%. It also plays a major role in accelerating angiogenesis and encouraging the propagation of fibroblasts. Similarly, Chu et al. developed a NIR + Cu-carbon dots biomaterial in which the wound closure rate reached 96% (control = 62%) after treatments for 14 days, while its H&E staining showed more collagen depositions, neovascularization and re-epithelization in comparison with the control group. However, NIR-induced hyperthermia has short-term antibacterial efficacy, so when it is stopped, the remaining pathogens cannot be effectively inhibited. Therefore, in order to address these concerns issues, some studies have suggested the encapsulation of antibiotics in combination therapies [33][28][34], see Figure 8 [7] and Figure 9 [35].
    Figure 8. Schematic concept of sol-to-gel phase transition of polyplex-loaded PEGPSMEU copolymers sols, subcutaneous administration, controlled released via diffusion, effective absorption onto skin and wound healing. Reprinted with permission from ref. [7]. Copyright © 2020 from Journal of Controlled Release, Elsevier.
    Figure 9. Illustration of the potential application of multifunctional IHs for cancer multi-therapy as well as regeneration after tissue damage. Reprinted with permission from ref. [35]. Copyright © 2020 Advance Health Care Materials, Wiley-VCH GmbH.

    2.3.3. Bone Regeneration

    According to Kim et al., alginate-based conjugating temperature-responsive poly(ε-caprolactone-co-lactide)-b-poly(ethylene glycol)-b-poly(ε-caprolactone-co-lactide) and O-phosphoryl-ethanolamine can be used as phosphorylation functional groups (PCLA-b-PEG-b-PCLA-/Alg) to obtain bioconjugate-injectable scaffold systems that have the ability to accelerate bone biomineralization [12] (Figure 10). When the temperature was elevated from room temperature to physiological temperature, these bioconjugates showed a sol–gel transition. In in vivo and in vitro situ biomineralization, the XRD analysis confirmed that such bioconjugate hydrogel could result in a reduction in crystalline hydroxyl apatite, and it also released BMP-2 (mitogenic factors) for more than three days. These BMP-2-containing PCLA-b-PEG-b-PCLA/Alg bioconjugate hydrogels also possess calcium deposition at the eroded sites, which suggests mineralization and bone regeneration; see Figure 10 [12][20].
    Figure 10. Schematic illustration of recruitment of host cells into PCLA-b-PEG-b-PCLA/BSA hydrogels and subsequent activation in response to DNA vaccine-bearing polyplexes released from these hydrogels. Reprinted with permission from ref. [7]. Copyright © 2020 from Journal of Controlled Release, Elsevier.

    3. Future Prospects

    3.1. Limitations and Outcomes/Overcomes

    Regarding their current prospective and ongoing research, hydrogel formulations have some limitations in their applications, clinical practices and sustainability. Many hydrogel systems (natural/synthetic), such as thermosensitive hydrogels, as mentioned, are free-flowing sols at a low temperature, while upon raising to body temperature (physiological temperature), they are converted to a stable visco-elastic gel phase, such as poly (phosphazene), pluronic and poly (N-isopropyl acrylamide). However, their biomedical uses are restricted due to their limited non-biodegradable and biocompatible characteristics, as shown in Table 1. However, poly (ester)-based copolymers are a good alternative for overcoming these limitations, but they still require more extensive research. Moreover, PEG and poly(ester)-based hydrogels (local drug-carriers) are not effective for prolonged therapeutics. Their oral and nasal route administrations are inappropriate, though they have been approved by the FDA for in vivo implantation. Similarly, injectable hydrogels used for proteins and peptide-controlled delivery, chemical interactions, structure compatibilities and burst release (when charged proteins are added to uncharged formulations) are also facing future challenges [12].
    Table 1. Injectable hydrogels synthesized through chemical and physical crosslinking methods, their application and limitations.
    Chemical/Physical Crosslinking Types of Hydrogel Material Hydrogel Synthesis Procedure Applications and Advantages Limitations and Disadvantages Reference
    Hydrophobic interaction Hydrophilic monomers and hydrophobic co-monomers Free radical copolymerization of a hydrophilic monomer with a hydrophobic co-monomer Absence of crosslinking agents and relative ease of production Poor mechanical characteristics [36]
    Ionic interaction Solution and multivalent ions of opposite charge Polyelectrolyte ionic interaction through simple ion exchange mechanisms and complex formation Crosslinking takes place at room temperature and physiological pH Properties can be fine-tuned by cationic and anionic constituents Limited to ionic polymers and sensitive to impurities [31]
    Hydrogen bond Polymeric functional groups of high electron density with electron-deficient hydrogen atom Self-assembly through secondary molecular interactions Increase in polymer concentration can increase the stability of gel Influx of water can disperse/dissolve the gel within short duration [32]
    Bulk polymerization Monomers and monomer-soluble initiators The polymerization reaction is initiated with radiation, ultraviolet or chemical catalysts at low rate of conversions A simple and versatile technique for preparing hydrogels with desired physical properties and forms Increase in viscosity during high rate of polymerization reaction can generate heat Weak polymer structure [37]
    Solution polymerization Ionic or neutral monomers with the multifunctional crosslinking agent Reaction initiated thermally with UV irradiation or by redox initiator system Control of temperature
    Performed in non-toxic aqueous medium at room temperature
    High polymerization rate
    To be washed to eliminate reactants, the polymers and other impurities [38]
    Suspension polymerization Hydrophilic monomers, initiators, cross-linkers and suspending agent The monomers and initiator are dispersed in the organic phase as a homogenous mixture Directly usable as powders, beads or microspheres
    Restricted to water insoluble polymer
    Cooling jacket required to dissipate heat
    Requirement of agitators and dispersant
    Grafting Viny polymers, initiators and crosslinking agents Covalent bonding of monomers on free radicals generated on stronger support structures Improve functional properties of the polymer Difficulty of characterizing side chains [40]
    Irradiation High energy gamma beams and electron beams as initiators Irradiation of aqueous polymer solution results in the formation of radicals and macroradicals on the polymer chains Pure, sterile, residue-free hydrogel
    Does not require catalyst and other additives
    Irradiation dose can control swelling capacity
    Irradiation can cause polymer degradation via chain scission and crosslinking events [41]
    Step growth polymerization Bi- or multifunctional monomers and each with attest two sites for bonding Multifunctional monomers react to form oligomers resulting in long chain polymers No initiator is required to start the polymerization and termination reactions Prolonged reaction times required to achieve a high degree of conversion and high molecular weights [42]
    In enzymatic stimuli responsiveness, fragile molecules, such as proteins, cells and drugs, are degraded or denatured by the use of cross-linker monomers and toxic catalysts. Homogenous encapsulation, loading and pre-mature release are also associated limitations and concerns [4].

    3.2. Injectable Formulation Challenges

    Here, researchers describe the ongoing prospective of a targeted drug delivery system that improves the therapeutic regimen and enables target-specific delivery. In addition, self-assembled nanocarriers and their active targeting receptors/antigen overexpression in tumor cells are prospective major therapeutic approaches.
    IHs, along with their specific applications, which have been already discussed, have some common notable concerns and require further exploration. The compatibility of the fragile molecules or cells with hydrogel crosslinkings and proliferation maintenance within a healthier environment are of the utmost importance, while they are essential for protecting DNA, peptides, proteins and oligonucleotides from enzymatic degradation or denaturation. Cytotoxicity and inflammatory responses need to be avoided by under-standing their interactions with the cellular and surrounding tissues. Low reproducibility; poorly defined structures; employed system considerations, including the gelation mechanism, rate kinetics, viscosity during the injection time; mechanical sturdiness after gelation; the degradation period; and release profile of bioactive factors should be properly taken in account [43]. It should be noted that these IHs must have application-specific design measurements related to their chemical–physical crosslinking and biological computability, which should be specific and responsive to certain medical conditions or pathogenesis [33][26].

    3.2.1. Mechanical Robustness

    The maintenance of a low viscosity and sustainability of sufficient elasticity in situ for repetitive load and volume is a major design challenge [44]. As these hydrogels are administered through a needle and syringe, in situ gelation and repetitive doses are of great concern. Shear thinning polymers, such as hyaluronic acid, which are currently used as a dermal filler, are being replaced by an injectable for cartilage replacement [2][45][46]. Thus, the polymer molecular weight, chains, extent of crosslinking and crosslinking mechanism and viscosity have a linear relationship with the molecular weight, while the elastic modulus has an inverse relation [15][26].

    3.2.2. Loading and Release of Therapeutic Agents

    The loading and release of therapeutic agents, such as small drug molecules, macromolecules (peptides, proteins, nucleic acid, etc.) or living cells, can be conveyed to the surrounding environment through IH carriers, which have respective physico-chemical characteristics. Their effective release is determined by the cargo-gel size, affinity and interactions. Currently, IHs in clinic practice include microparticle depot systems (small molecules or biologics). The most commonly available depot formulations are lidocaine (anesthetic agent), with a number of hyaluronic acid hydrogel injectables that have been approved for facial corrections. Hydrogel meshes disturb lidocaine release due to its rapid release from these gels. Similarly, the elution of other drugs from hydrogel formulations for the sustained release of proteins/drugs in wound dressings is vital [15]. In such formulations, the hydrogel mesh size should be decreased via physical/chemical crosslinking to agitate the solute elution or increase its affinity to enhance its retention time [36].

    3.2.3. Hydrogel Bioactivity

    The bulk hydrogel material must penetrate, alter and degrade bulk hydrogel materials for tissue regeneration purposes. For hydrogel bioactivity, it is essential that cells or growth factors stick to adhesive natural or synthetic materials such as hyaluronic acid, fibrin or gelatin. For instance, in some ongoing clinical trials, e.g., NCT04115345, NCT04115345 and NCT00981006, the hydrogel bioactivity of gelatin is used with cells and/growth factors. These bioactive hydrogels expedite kidney or myocardium tissue injury healing by generating a suitable cell-adhesive microenvironment. Some non-adhesive polymers, such as PEG and polyacrylamide, must be amended chemically with adhesive ligands to assist cell penetration and attachment. Conversely, some commercially available hydrogels, e.g., TraceIT®, which is used for targeting tumor margins, have the design limitation of rapid biodegradation. Thus, it is essential to use or substitute a polymer hydrogel that degrades gradually over weeks to months [1][10][11][15][47].

    3.2.4. Immunological Compatibility

    Provoking immunological responses to IH biomaterials has been a considerable area of research in recent decades. Thus, in injectable hydrogel formulations, it is imperative to minimize all kinds of immune responses during in situ gel transitions [48][49]. Immunological responses are considered as the worst consequences of biomaterial injection, insertion and implantation, including inflammatory cascades, fibrosis and hypersensitivity reactions. These responses are considered harmful in their own prospects, associated physico-chemical shifts and responsiveness (i.e., changes in the local pH or temperature), which can affect the hydrogel material performance, function and further application [50]. Thus, minimalizing IH-associated host-immune responses is a critical biological design parameter. Cell-based drug delivery systems (erythrocytes, leukocytes, platelets, cancer cells and hepatic cell membrane biomimetic nanosystem fabrications) can be utilized for immunocompatibility, immune escaping, prolonged release and sustained release [51][52][53][54][55][56][57][58][59][60][61][62][63]. Some hydrogels have been used in these cell-based fabricated biomimetic nanosystems [64].

    3.2.5. Technological Challenges

    Technological challenges, including chemistry, good manufacturing practices (GMP), controlled and well-defined regulatory guidelines, practical adoptability and high prices are major hurdles for successful clinical translations of hydrogel-based delivery systems. It is estimated that hydrogel fabrication system development and fabrication costs through clinical translation range from USD 50 million up to USD 800 million.

    3.2.6. Scale-Up Strategies and GMP Processes

    As most hydrogel systems are generated and synthesized at a small pilot-plant scale at pre-clinical stages, current good manufacturing practices (cGMP) for the clinical translation and integration of biomaterial-based hydrogels in large-scaled systems and their compatibility are required. Robustness, batch-to-batch variations, safety profiles, reproducibility and proficiency are predictable when executed at a large scale. Moreover, the high water content of hydrogels makes the synthesis, fabrication, storage, sustainability, sterilization and all relevant optimization processes even more demanding.

    3.2.7. Regulatory Approvals

    As researchers mentioned earlier, regulatory affairs and FDA approval are time-consuming processes and take years—from laboratory synthesis to market launch and surveillance. The diversity in injectable hydrogel scaffolds and the assortment of employed crosslinking polymers and biomaterials render their regulatory classification and approval challenging [15].


    1. Lee, J.H. Injectable hydrogels delivering therapeutic agents for disease treatment and tissue engineering. Biomater. Res. 2018, 22, 27.
    2. Chao, Y.; Chen, Q.; Liu, Z. Smart Injectable Hydrogels for Cancer Immunotherapy. Adv. Funct. Mater. 2020, 30, 1902785.
    3. Wang, S.; Zheng, H.; Zhou, L.; Cheng, F.; Liu, Z.; Zhang, H.; Wang, L.; Zhang, Q. Nanoenzyme-Reinforced Injectable Hydrogel for Healing Diabetic Wounds Infected with Multi-Drug Resistant Bacteria. Nano Lett. 2020, 20, 5149–5158.
    4. Liu, S.; Guo, R.; Li, C.; Lu, C.; Yang, G.; Wang, F.; Nie, J.; Ma, C.; Gao, M. POSS hybrid hydrogels: A brief review of synthesis, properties and applications. Eur. Polym. J. 2021, 143, 110180.
    5. Chatterjee, S.; Hui, P.C.L. Review of applications and future prospects of stimuli-responsive hydrogel based on thermo-responsive biopolymers in drug delivery systems. Polymers 2021, 13, 2086.
    6. Tan, H.; Marra, K.G. Injectable, biodegradable hydrogels for tissue engineering applications. Materials 2010, 3, 1746–1767.
    7. Li, Y.; Yang, H.Y.; Lee, D.S. Advances in biodegradable and injectable hydrogels for biomedical applications. J. Control. Release 2021, 330, 151–160.
    8. Nguyen, Q.V.; Huynh, D.P.; Park, J.H.; Lee, D.S. Injectable polymeric hydrogels for the delivery of therapeutic agents: A review. Eur. Polym. J. 2015, 72, 602–619.
    9. Alonso, J.M.; Del Olmo, J.A.; Gonzalez, R.P.; Saez-martinez, V. Injectable hydrogels: From laboratory to industrialization. Polymers 2021, 13, 650.
    10. Yao, Q.; Lan, Q.H.; Jiang, X.; Du, C.C.; Zhai, Y.Y.; Shen, X.; Xu, H.L.; Xiao, J.; Kou, L.; Zhao, Y.Z. Bioinspired biliverdin/silk fibroin hydrogel for antiglioma photothermal therapy and wound healing. Theranostics 2020, 10, 11719–11736.
    11. Du, X.; Zhou, J.; Shi, J.; Xu, B. Supramolecular Hydrogelators and Hydrogels: From Soft Matter to Molecular Biomaterials. Chem. Rev. 2015, 115, 13165–13307.
    12. Kim, S.H.; Thambi, T.; Giang Phan, V.H.; Lee, D.S. Modularly engineered alginate bioconjugate hydrogel as biocompatible injectable scaffold for in situ biomineralization. Carbohydr. Polym. 2020, 233, 115832.
    13. Sun, Y.; Nan, D.; Jin, H.; Qu, X. Recent Advances of Injectable Hydrogels for Drug Delivery and. Polym. Test. 2020, 81, 106283.
    14. Suflet, D.M.; Popescu, I.; Pelin, I.M.; Ichim, D.L.; Daraba, O.M.; Constantin, M.; Fundueanu, G. Dual cross-linked chitosan/pva hydrogels containing silver nanoparticles with antimicrobial properties. Pharmaceutics 2021, 13, 1461.
    15. Mandal, A.; Clegg, J.R.; Anselmo, A.C.; Mitragotri, S. Hydrogels in the clinic. Bioeng. Transl. Med. 2020, 5, e10158.
    16. Eslahi, N.; Abdorahim, M.; Simchi, A. Smart Polymeric Hydrogels for Cartilage Tissue Engineering: A Review on the Chemistry and Biological Functions. Biomacromolecules 2016, 17, 3441–3463.
    17. De France, K.J.; Cranston, E.D.; Hoare, T. Mechanically Reinforced Injectable Hydrogels. ACS Appl. Polym. Mater. 2020, 2, 1016–1030.
    18. Zhang, X.; Tan, B.; Wu, Y.; Zhang, M.; Liao, J. A review on hydrogels with photothermal effect in wound healing and bone tissue engineering. Polymers 2021, 13, 2100.
    19. Ilochonwu, B.C.; Urtti, A.; Hennink, W.E.; Vermonden, T. Intravitreal hydrogels for sustained release of therapeutic proteins. J. Control. Release 2020, 326, 419–441.
    20. Fan, D.Y.; Tian, Y.; Liu, Z.J. Injectable Hydrogels for Localized Cancer Therapy. Front. Chem. 2019, 7, 675.
    21. Giang Phan, V.H.; Duong, H.T.T.; Thambi, T.; Nguyen, T.L.; Turabee, M.H.; Yin, Y.; Kim, S.H.; Kim, J.; Jeong, J.H.; Lee, D.S. Modularly engineered injectable hybrid hydrogels based on protein-polymer network as potent immunologic adjuvant in vivo. Biomaterials 2019, 195, 100–110.
    22. Nandi, R.; Yucknovsky, A.; Mazo, M.M.; Amdursky, N. Exploring the inner environment of protein hydrogels with fluorescence spectroscopy towards understanding their drug delivery capabilities. J. Mater. Chem. B 2020, 8, 6964–6974.
    23. Liu, C.; Zhang, Q.; Zhu, S.; Liu, H.; Chen, J. Preparation and applications of peptide-based injectable hydrogels. RSC Adv. 2019, 9, 28299–28311.
    24. Xiao, Y.; Gu, Y.; Qin, L.; Chen, L.; Chen, X.; Cui, W.; Li, F.; Xiang, N.; He, X. Colloids and Surfaces B: Biointerfaces Injectable thermosensitive hydrogel-based drug delivery system for local cancer therapy. Colloids Surf. B Biointerfaces 2021, 200, 111581.
    25. Afinjuomo, F.; Abdella, S.; Youssef, S.H. Inulin and Its Application in Drug Delivery. Pharmaceuticals 2021, 14, 855.
    26. Gil, M.S.; Cho, J.; Thambi, T.; Giang Phan, V.H.; Kwon, I.; Lee, D.S. Bioengineered robust hybrid hydrogels enrich the stability and efficacy of biological drugs. J. Control. Release 2017, 267, 119–132.
    27. Ma, H.; He, C.; Cheng, Y.; Li, D.; Gong, Y.; Liu, J.; Tian, H.; Chen, X. PLK1shRNA and doxorubicin co-loaded thermosensitive PLGA-PEG-PLGA hydrogels for osteosarcoma treatment. Biomaterials 2014, 35, 8723–8734.
    28. Mathew, A.P.; Uthaman, S.; Cho, K.H.; Cho, C.S.; Park, I.K. Injectable hydrogels for delivering biotherapeutic molecules. Int. J. Biol. Macromol. 2018, 110, 17–29.
    29. Dimatteo, R.; Darling, N.J.; Segura, T. In situ forming injectable hydrogels for drug delivery and wound repair. Adv. Drug Deliv. Rev. 2018, 127, 167–184.
    30. Overstreet, D.J.; Dutta, D.; Stabenfeldt, S.E.; Vernon, B.L. Injectable hydrogels. J. Polym. Sci. Part B Polym. Phys. 2012, 50, 881–903.
    31. Won, J.E.; Wi, T.I.; Lee, C.M.; Lee, J.H.; Kang, T.H.; Lee, J.W.; Shin, B.C.; Lee, Y.J.; Park, Y.M.; Han, H.D. NIR irradiation-controlled drug release utilizing injectable hydrogels containing gold-labeled liposomes for the treatment of melanoma cancer. Acta Biomater. 2021, 136, 508–518.
    32. Wei, W.; Li, H.; Yin, C.; Tang, F. Research progress in the application of in situ hydrogel system in tumor treatment. Drug Deliv. 2020, 27, 460–468.
    33. Hu, C.; Zhang, F.; Long, L.; Kong, Q.; Luo, R.; Wang, Y. Dual-responsive injectable hydrogels encapsulating drug-loaded micelles for on-demand antimicrobial activity and accelerated wound healing. J. Control. Release 2020, 324, 204–217.
    34. Zhao, L.; Niu, L.; Liang, H.; Tan, H.; Liu, C.; Zhu, F. PH and Glucose Dual-Responsive Injectable Hydrogels with Insulin and Fibroblasts as Bioactive Dressings for Diabetic Wound Healing. ACS Appl. Mater. Interfaces 2017, 9, 37563–37574.
    35. Poustchi, F.; Amani, H.; Ahmadian, Z.; Niknezhad, S.V.; Mehrabi, S.; Santos, H.A.; Shahbazi, M.A. Combination Therapy of Killing Diseases by Injectable Hydrogels: From Concept to Medical Applications. Adv. Healthc. Mater. 2021, 10, e2001571.
    36. Kong, L.; Wu, Z.; Zhao, H.; Cui, H.; Shen, J.; Chang, J.; Li, H.; He, Y. Bioactive Injectable Hydrogels Containing Desferrioxamine and Bioglass for Diabetic Wound Healing. ACS Appl. Mater. Interfaces 2018, 10, 30103–30114.
    37. Okay, O. Self-healing hydrogels formed via hydrophobic interactions. In Supramolecular Polymer Networks and Gels; Springer: Cham, Switzerland, 2015; Volume 268, ISBN 9783319154046.
    38. Lin, J.; Zheng, S.Y.; Xiao, R.; Yin, J.; Wu, Z.L.; Zheng, Q.; Qian, J. Constitutive behaviors of tough physical hydrogels with dynamic metal-coordinated bonds. J. Mech. Phys. Solids 2020, 139, 103935.
    39. Hennink, W.E.; van Nostrum, C.F. Novel crosslinking methods to design hydrogels. Adv. Drug Deliv. Rev. 2012, 64, 223–236.
    40. Ahmed, E.M. Hydrogel: Preparation, characterization, and applications: A review. J. Adv. Res. 2015, 6, 105–121.
    41. Qiu, X.; Hu, S. “Smart” materials based on cellulose: A review of the preparations, properties, and applications. Materials 2013, 6, 738–781.
    42. Caló, E.; Khutoryanskiy, V.V. Biomedical applications of hydrogels: A review of patents and commercial products. Eur. Polym. J. 2015, 65, 252–267.
    43. Jacob, S.; Nair, A.B.; Shah, J.; Sreeharsha, N.; Gupta, S.; Shinu, P. Emerging role of hydrogels in drug delivery systems, tissue engineering and wound management. Pharmaceutics 2021, 13, 357.
    44. Guvendiren, M.; Lu, H.D.; Burdick, J.A. Shear-thinning hydrogels for biomedical applications. Soft Matter 2012, 8, 260–272.
    45. Yu, L.; Ding, J. Injectable hydrogels as unique biomedical materials. Chem. Soc. Rev. 2008, 37, 1473–1481.
    46. Liang, K.; Bae, K.H.; Kurisawa, M. Recent advances in the design of injectable hydrogels for stem cell-based therapy. J. Mater. Chem. B 2019, 7, 3775–3791.
    47. Branco, M.C.; Pochan, D.J.; Wagner, N.J.; Schneider, J.P. The effect of protein structure on their controlled release from an injectable peptide hydrogel. Biomaterials 2010, 31, 9527–9534.
    48. Taha, T.A. Optical properties of PVC/Al2O3 nanocomposite films. Polym. Bull. 2019, 76, 903–918.
    49. Said, H.M.; Alla, S.G.A.; El-Naggar, A.W.M. Synthesis and characterization of novel gels based on carboxymethyl cellulose/acrylic acid prepared by electron beam irradiation. React. Funct. Polym. 2004, 61, 397–404.
    50. Zhang, L.; Ren, X.; Zhang, Y.; Zhang, K. Step-Growth Polymerization Method for Ultrahigh Molecular Weight Polymers. ACS Macro Lett. 2019, 8, 948–954.
    51. Sun, Y.; Su, J.; Liu, G.; Chen, J.; Zhang, X.; Zhang, R.; Jiang, M.; Qiu, M. Advances of blood cell-based drug delivery systems. Eur. J. Pharm. Sci. 2017, 96, 115–128.
    52. Su, J.; Zhang, R.; Lian, Y.; Kamal, Z.; Cheng, Z.; Qiu, Y.; Qiu, M. Preparation and characterization of erythrocyte membrane-camouflaged berberine hydrochloride-loaded gelatin nanoparticles. Pharmaceutics 2019, 11, 93.
    53. Liu, W.; Ruan, M.; Wang, Y.; Song, R.; Ji, X.; Xu, J.; Dai, J.; Xue, W. Light-Triggered Biomimetic Nanoerythrocyte for Tumor-Targeted Lung Metastatic Combination Therapy of Malignant Melanoma. Small 2018, 14, e1801754.
    54. Malhotra, S.; Dumoga, S.; Sirohi, P.; Singh, N. Red Blood Cells-Derived Vesicles for Delivery of Lipophilic Drug Camptothecin. ACS Appl. Mater. Interfaces 2019, 11, 22141–22151.
    55. Kamal, Z.; Su, J.; Qiu, M. Erythrocytes modified (coated) gold nanoparticles for effective drug delivery. In Metal Nanoparticles for Drug Delivery and Diagnostic Applications; Micro and Nanotechnologies; Elsevier: Amsterdam, The Netherlands, 2020; pp. 13–29. ISBN 978-0-12-816960-5.
    56. Li, L.L.; Xu, J.H.; Qi, G.B.; Zhao, X.; Yu, F.; Wang, H. Core-shell supramolecular gelatin nanoparticles for adaptive and “on-demand” antibiotic delivery. ACS Nano 2014, 8, 4975–4983.
    57. Pornpattananangkul, D.; Zhang, L.; Olson, S.; Aryal, S.; Obonyo, M.; Vecchio, K.; Huang, C.M.; Zhang, L. Bacterial toxin-triggered drug release from gold nanoparticle-stabilized liposomes for the treatment of bacterial infection. J. Am. Chem. Soc. 2011, 133, 4132–4139.
    58. Wang, F.; Gao, W.; Thamphiwatana, S.; Luk, B.T.; Angsantikul, P.; Zhang, Q.; Hu, C.M.J.; Fang, R.H.; Copp, J.A.; Pornpattananangkul, D.; et al. Hydrogel retaining toxin-absorbing nanosponges for local treatment of methicillin-resistant Staphylococcus aureus infection. Adv. Mater. 2015, 27, 3437–3443.
    59. Lin, A.; Liu, Y.; Zhu, X.; Chen, X.; Liu, J.; Zhou, Y.; Qin, X.; Liu, J. Bacteria-Responsive Biomimetic Selenium Nanosystem for Multidrug-Resistant Bacterial Infection Detection and Inhibition. ACS Nano 2019, 13, 13965–13984.
    60. Huang, P.; Wang, D.; Su, Y.; Huang, W.; Zhou, Y.; Cui, D.; Zhu, X.; Yan, D. Combination of small molecule prodrug and nanodrug delivery: Amphiphilic drug-drug conjugate for cancer therapy. J. Am. Chem. Soc. 2014, 136, 11748–11756.
    61. Chen, S. Biomimetic Nanoscale Systems for pH-Triggered Intracellular Drug Delivery. Ph.D. Thesis, Imperial College London, London, UK, 2017.
    62. Chu, M.; Zhang, M.B.; Liu, Y.C.; Kang, J.R.; Chu, Z.Y.; Yin, K.L.; Ding, L.Y.; Ding, R.; Xiao, R.X.; Yin, Y.N.; et al. Role of berberine in the treatment of methicillin-resistant staphylococcus aureus infections. Sci. Rep. 2016, 6, 24748.
    63. Gao, M.; Liang, C.; Song, X.; Chen, Q.; Jin, Q.; Wang, C.; Liu, Z. Erythrocyte-membrane-enveloped perfluorocarbon as nanoscale artificial red blood cells to relieve tumor hypoxia and enhance cancer radiotherapy. Adv. Mater. 2017, 29, 1701429.
    64. Zhang, Y.; Zhang, J.; Chen, W.; Angsantikul, P.; Spiekermann, K.A.; Fang, R.H.; Gao, W.; Zhang, L. Erythrocyte membrane-coated nanogel for combinatorial antivirulence and responsive antimicrobial delivery against Staphylococcus aureus infection. J. Control. Release 2017, 263, 185–191.
    Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to : , , ,
    View Times: 989
    Revisions: 2 times (View History)
    Update Date: 08 Apr 2022
    Table of Contents


      Are you sure to Delete?

      Video Upload Options

      Do you have a full video?
      If you have any further questions, please contact Encyclopedia Editorial Office.
      Aboelhamd, M.; Almawash, S.; Osman, S.; Mustafa, G. Design Challenges and Limitations of Injectable Hydrogels. Encyclopedia. Available online: (accessed on 24 March 2023).
      Aboelhamd M, Almawash S, Osman S, Mustafa G. Design Challenges and Limitations of Injectable Hydrogels. Encyclopedia. Available at: Accessed March 24, 2023.
      Aboelhamd, Mohamed, Saud Almawash, Shaaban Osman, Gulam Mustafa. "Design Challenges and Limitations of Injectable Hydrogels" Encyclopedia, (accessed March 24, 2023).
      Aboelhamd, M., Almawash, S., Osman, S., & Mustafa, G. (2022, April 07). Design Challenges and Limitations of Injectable Hydrogels. In Encyclopedia.
      Aboelhamd, Mohamed, et al. "Design Challenges and Limitations of Injectable Hydrogels." Encyclopedia. Web. 07 April, 2022.